News | Mammography | April 04, 2017

Five-year study employed Kubtec’s Mozart System with TomoSpec technology

digital breast tomosynthesis, DBT, 3-D mammography, breast imaging, re-excision rate, breast surgeries, ECR 2017, Kubtec Mozart System

April 4, 2017 — A study presented at the 2017 European Congress of Radiology (ECR) has concluded that adding digital breast tomosynthesis (DBT) is emerging as promising technology for surgical planning, as it offers a better view of lesion margins than mammography alone. The study results were presented at ECR 2017, March 1-5 in Vienna, Austria, by Alessia Milan, Ph.D., from the University of Turin.

The five-year study of 925 breast cancer patients demonstrated that the use of DBT can reduce re-excision rates by up to 50 percent.

"Margin status is one of the most important predictors for local recurrence following breast cancer surgery, and accurate pre-operative staging helps to plan appropriate surgical treatment and reduce the consequences of re-excision," Milan told meeting attendees. "These consequences can include emotional burden for the patient, a worse cosmetic outcome and higher costs."

The latest tool to use digital tomosynthesis to drive a reduction in positive margins is the Mozart System with TomoSpec Technology from Kubtec. The company said it is the first and only 3-D specimen tomosynthesis system designed specifically for intraoperative use.

Rather than producing a single 2-D planar view of multiple tissue layers, the Mozart System uses 3-D tomosynthesis technology to eliminate tissue interference by digitally removing overlying or underlying tissue in 1mm slices. This means that potential extensions of the cancer, radiating laterally or deep to the lesion, can be seen with greater clarity, helping to decrease the risk of positive margins and optimizing the cosmetic outcome of the procedure.

The Mozart System uses digital tomosynthesis to provide a three-dimensional solution to a three-dimensional problem during the treatment stage of breast cancer.

For more information: www.kubtec.com


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
Subscribe Now